// App-Quantinova.ai

506 : Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.

Researchers

Presenter

  • Nadia Harbeck

Principal Investigators

  • Matthias Christgen

  • Marianne Just

  • Joke Tio

  • Anke Kleine-Tebbe

  • Cornelia Liedtke

  • Ronald E. Kates

  • Daniel Hofmann

  • Rachel Wuerstlein

  • Hans Heinrich Kreipe

  • Ulrike Nitz

  • Jochem Potenberg

  • Bahriye Aktas

  • Claudia Schumacher

  • Helmut Forstbauer

  • Doris Augustin

  • Stefan Kraemer

  • Michael Wilhelm Braun

  • Sherko Kummel

Medical Centers

  • Elisabeth Hospital, Kassel, Germany

  • Department of Obstetrics & Gynecology, University Hospital of Cologne, Cologne, Germany

  • University of Schleswig-Holstein Campus Luebeck, Luebeck, Germany

  • AGO & Kliniken Essen Mitte, Essen, Germany

  • Klinikum Deggendorf, Deggendorf, Germany

  • Oncologic Practice Bielefeld, Bielefeld, Germany

  • University of Munich, Otterfing, Germany

  • DRK Kliniken Berlin Kopenick, Berlin, Germany

  • University Hospital of Essen, Essen, Germany

  • Rotkreuzklinikum, Munich, GermanyREK Consulting, Otterfing, GermanyDepartment of Hematology, Waldkrankenhaus Spandau, Berlin, Germany

  • Praxisnetzwerk Hamatologie / intern. Onkologie, Troisdorf, Germany

  • Geriatric Breast Center, Evangelina Bethesda Hospital for Breast Diseases, Nordrhein-Westfalen, Germany

  • West German Study Group, Moenchengladbach, Germany

  • Hannover Medical School, Hannover, Germany

  • University Hospital of Muenster, Muenster, Germany

  • University of Munich, Munich, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Circulating tumor cells

  • Proliferation marker protein Ki-67

  • Human epidermal growth factor receptor 2

  • Iron‐corrected T1

Drug/Treatment

  • Trastuzumab

  • Tamoxifen

  • Trastuzumab emtansine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved